CNBC's Jim Cramer on Wednesday identified two biotechnology stocks that he thinks could climb.» Read More
Amgen Inc. fell $2.62 or 2.0 percent, to $127.39. Biogen Idec fell $10.13 or 2.9 percent, to $334.39. Celgene Corp. fell $1.19 or 1.3 percent, to $87.15.
PARIS, July 31- French drugmaker Sanofi raised its full-year profit forecast on Thursday along with a set of stronger than expected quarterly earnings driven by its rare disease and diabetes businesses and higher sales in emerging markets.
Amgen Inc. rose $6.70 or 5.4 percent, to $130.01. Biogen Idec rose $2.79 or. 8 percent, to $344.52. Celgene Corp. rose$. 61 or. 7 percent, to $88.34.
*Twitter shares rally a day after results. Among the biggest positives were bank shares, with the S&P financial index up 0.4 percent, helping to support the S&P 500. Shares of Wells Fargo gained 1.1 percent to $52.10.
NEW YORK, July 30- The S&P 500 was near flat on Wednesday after the Federal Reserve gave a rosier assessment of the U.S. economy while reaffirming that it is in no hurry to raise interest rates.
Amgen Inc. rose $6.40 or 5.2 percent, to $129.71. Biogen Idec rose $2.63 or. 8 percent, to $344.36. Celgene Corp. rose $1.33 or 1.5 percent, to $89.06.
*Twitter rallies after blockbuster results. NEW YORK, July 30- U.S. stocks were flat on Wednesday, paring earlier gains as a strong read on second-quarter economic growth sparked concerns the Federal Reserve may adjust its stimulus earlier than expected.
Amgen Inc. rose $6.70 or 5.4 percent, to $130.01. Biogen Idec rose $4.40 or 1.3 percent, to $346.13. Celgene Corp. rose $1.63 or 1.9 percent, to $89.36.
*Twitter rallies after blockbuster results. *Biotechs rally on Amgen results, Regeneron trial data. Twitter Inc surged on heavy volume, jumping 25 percent to $48.25 in its biggest one-day advance ever after reporting that monthly active users had risen a better-than-expected 24 percent in the second quarter.
*Sanofi to file drug for US and EU approval by year-end. PARIS, July 30- A new drug being developed by French drugmaker Sanofi and U.S. partner Regeneron cut "bad" LDL cholesterol more than placebo and existing treatments in nine late-stage clinical trials, the companies said on Wednesday.
July 29- Amgen Inc on Tuesday said it would cut up to 15 percent of its work force and close plants in a series of moves aimed at reallocating resources as it prepares to introduce new medicines it hopes will drive future growth.
July 29- Amgen Inc on Tuesday said it would cut up to 15 percent of its global work force and close plants as part of a series of moves aimed at reallocating resources as it prepares for the eventual launch of medicines it hopes will drive future growth.
Amgen posted higher-than-expected profit and said it would cut 12 to 15 percent of its workforce and close two plants.
July 29- Amgen Inc on Tuesday posted higher-than-expected second-quarter profit in a rebound from a disappointing first quarter, helped by strong sales of its rheumatoid arthritis drug Enbrel, and it significantly raised its full-year earnings forecast.
Biologic drugmaker Amgen said Tuesday that it will lay off 12 to 15 percent of its worldwide workforce and close four sites, even as it reported stellar second-quarter results that trounced Wall Street expectations. Amgen also raised its forecasts for its 2014 profit and revenue, driving up its shares.
Amgen Inc. fell$. 19 or. 2 percent, to $122.65. Biogen Idec rose$. 94 or. 3 percent, to $336.39. Celgene Corp. rose$. 48 or. 6 percent, to $87.64.
The Fed meets for two days, starting Tuesday, and is widely expected to taper back its monthly bond buying program by another $10 billion to $25 billion - and do little else.
WASHINGTON— Standard& Poor's releases S&P/Case-Shiller index of home prices for May, 9 a.m.. WASHINGTON— The Conference Board releases the Consumer Confidence Index for July, 10 a.m.. WASHINGTON— House Energy and Commerce subcommittee hearing on EPA's proposed clean power plan and grid reliability challenges.
Amgen Inc. fell$. 84 or. 7 percent, to $122.00. Biogen Idec fell$. 40 or. 1 percent, to $335.05. Celgene Corp. fell$. 19 or. 2 percent, to $86.97.
Amgen Inc. fell$. 67 or. 5 percent, to $122.17. Biogen Idec fell$. 97 or. 3 percent, to $334.48. Celgene Corp. fell$. 48 or. 6 percent, to $86.68.